NASDAQ:OBSV - Obseva Stock Price, Forecast & News

Obseva trades on the NASDAQ under the ticker symbol "OBSV."

Obseva SA (NASDAQ:OBSV) issued its quarterly earnings results on Thursday, November, 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.82) by $0.19. View Obseva's Earnings History.

Obseva is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Obseva.

4 brokerages have issued twelve-month target prices for Obseva's shares. Their forecasts range from $4.00 to $40.00. On average, they expect Obseva's stock price to reach $24.75 in the next twelve months. This suggests a possible upside of 619.5% from the stock's current price. View Analyst Price Targets for Obseva.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obseva in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Obseva.

Media headlines about OBSV stock have trended very negative this week, InfoTrie Sentiment reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Obseva earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Obseva.

Obseva saw a increase in short interest in January. As of January 31st, there was short interest totalling 1,100,000 shares, an increase of 23.6% from the January 15th total of 890,200 shares. Based on an average trading volume of 955,200 shares, the days-to-cover ratio is presently 1.2 days. Currently, 5.1% of the company's stock are sold short. View Obseva's Current Options Chain.

Some companies that are related to Obseva include BioXcel Therapeutics (BTAI), Molecular Templates (MTEM), Clovis Oncology (CLVS), ZIOPHARM Oncology (ZIOP), XBiotech (XBIT), Crinetics Pharmaceuticals (CRNX), TherapeuticsMD (TXMD), Ardelyx (ARDX), AC Immune (ACIU), MacroGenics (MGNX), Kura Oncology (KURA), Axovant Sciences (AXON), Assembly Biosciences (ASMB), Magenta Therapeutics (MGTA) and Puma Biotechnology (PBYI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Obseva investors own include Allena Pharmaceuticals (ALNA), Viking Therapeutics (VKTX), Amicus Therapeutics (FOLD), Corbus Pharmaceuticals (CRBP), Gilead Sciences (GILD), Progenics Pharmaceuticals (PGNX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Trevena (TRVN) and AcelRx Pharmaceuticals (ACRX).

(OBSV) raised $98 million in an initial public offering on Thursday, January 26th 2017. The company issued 6,500,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

Obseva's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (1.45%), Point72 Asset Management L.P. (0.99%), Credit Suisse AG (0.76%), Renaissance Technologies LLC (0.49%), Pictet Asset Management Ltd. (0.33%) and Wedbush Securities Inc. (0.30%).

OBSV stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and Goldman Sachs Group Inc..

OBSV stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Pictet Asset Management Ltd., Renaissance Technologies LLC, Wedbush Securities Inc., Ikarian Capital LLC, Zurcher Kantonalbank Zurich Cantonalbank, Geode Capital Management LLC and Acadian Asset Management LLC.

Shares of OBSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OBSV stock can currently be purchased for approximately $3.44.

Obseva has a market capitalization of $156.45 million. The company earns $-76,720,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Obseva employs 43 workers across the globe.View Additional Information About Obseva.

The official website for Obseva is http://www.obseva.com/.

Obseva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company can be reached via phone at 41-22-552-3840 or via email at [email protected]